DEA Production Quotas for Medical Cannabis: What We Know

As Marijuana Moment reports, the DEA’s proposed 2027 aggregate production quotas, released for public inspection on November 9 and scheduled for Federal Register publication on November 10, are mostly a story about psychedelics. The notice raises the 2027 production quotas for several psychedelic compounds used in research and holds the Schedule I marijuana figures at 2026 levels. Inside the same document is a short passage on cannabis. The DEA confirms that it is developing separate DEA production quotas for qualifying Schedule III marijuana, marijuana extracts, and naturally derived delta-9-THC, that it is evaluating data and methodologies to estimate legitimate national needs, and that it will publish the proposed amounts in their own notice. Marijuana Moment, Nov. 9, 2026 · Federal Register public inspection, Nov. 9, 2026 · DEA proposed 2027 APQ notice (PDF)

That short passage is why the notice matters to businesses pursuing federal registration. The important issue is not simply whether quotas are coming. They were always part of the April framework. The issue is what the eventual proposal will look like, and this notice gives only a partial view. What follows is my own reading of what those few sentences mean.

What the DEA has, and has not, announced

The notice does not establish numerical Schedule III medical marijuana quotas or announce when that separate proposal will appear.

The proposed 6,675,000-gram marijuana quota in the current document concerns Schedule I marijuana. It is not a proposed cap on the qualifying Schedule III medical marijuana market. DEA proposed 2027 APQ notice (PDF)

That distinction matters. Reading a marijuana production figure without identifying which federal category it covers can create a misleading impression of what the DEA is proposing.

Quotas were already part of the April framework

This is not the first time production quotas have appeared in the federal medical marijuana framework.

The April rescheduling order expressly addressed the Single Convention’s quota requirements. The resulting registration provision, 21 C.F.R. § 1301.13(k), directs the DEA to consider treaty requirements, including applicable quota requirements, when evaluating applications. The rule’s explanation also states that state-licensed marijuana must satisfy the Convention’s quota requirements. 91 Fed. Reg. 22,714 (Apr. 28, 2026) · 21 C.F.R. § 1301.13(k)

In other words, the latest announcement concerns implementation of an existing component of the framework, rather than the first introduction of production controls.

There is also a terminology issue worth keeping straight: the Single Convention’s schedules are not the same as the schedules under the Controlled Substances Act. Moving qualifying marijuana to Schedule III under domestic law does not, by itself, eliminate the treaty-related controls addressed in the April rescheduling order. 91 Fed. Reg. 22,714 (Apr. 28, 2026) · 21 C.F.R. § 1301.13(k)

What this notice may tell us, and what it does not

The current document is the DEA’s routine annual proposal for Schedule I and II substances: proposed figures, a 30-day comment period once published, and a final order afterward. That is the process the agency has used for years, and it is reasonable to expect the Schedule III proposal to arrive in a similar form, with a public proposal, a comment window, and estimates described as legitimate national need. DEA proposed 2027 APQ notice (PDF) · Marijuana Moment, Nov. 9, 2026

That is where the clue ends. The notice says nothing about the Schedule III amounts, the data the DEA will rely on, or how it will account for differences among state medical programs. I would not read the Schedule I figures as a preview of how the medical market will be treated. The two categories cover different material and serve different purposes.

One structural point from the established system is worth knowing, without going further into the mechanics than this article needs to. Under 21 U.S.C. § 826, the federal quota system distinguishes between an aggregate national production quantity and the individual quotas issued to registered manufacturers. Whether and how that two-level structure carries over to Schedule III medical marijuana is one of the things the separate notice will have to address. Until it does, a national number, if one is proposed, would not by itself tell an individual business how much it may produce. 21 U.S.C. § 826

This is different from state canopy licensing

There is a useful comparison for California operators. California’s cultivation license categories depend in part on canopy size and lighting type. That is a different regulatory question from how much of a controlled substance should be produced to satisfy estimated needs. One concerns the authorized cultivation area and license category. The other concerns production quantities. DCC, cultivation licensing

Neither should be treated as a substitute for the other. The federal medical marijuana registration rule expressly limits registered manufacturing activities to the scope of the underlying state license, and a business should not assume that its state-authorized footprint translates into a federal production allowance, or that a federal allowance would let it disregard state restrictions. 91 Fed. Reg. 22,714 (Apr. 28, 2026) · 21 C.F.R. § 1301.13(k)

Registration is not the end of the analysis

DOJ’s October 30 registration announcement identified facility inspections, production controls, and quota determinations as part of the additional review applicable to manufacturer and distributor applications. It also emphasized that state licensure does not automatically establish federal registration eligibility, a point the Minnesota and D.C. orders to show cause have since made concrete. DOJ, Oct. 30, 2026

For businesses, I would separate three questions:

Those questions are related, but they are not interchangeable. A cultivation expansion, supply commitment, or manufacturing forecast should not rest solely on the assumption that obtaining a federal registration resolves every operational issue. That does not mean businesses should cut production or abandon expansion plans. It means the federal production component should be treated as an unresolved planning issue, not an afterthought.

What should operators do now?

Watch for the separate Schedule III notice, and plan to read the proposal and its comment period closely when it appears. In the meantime, it does no harm to have the business’s own production records in order: historical medical sales, inventory, production records, and the assumptions behind future demand. The goal is not to guess the DEA’s methodology or to assume the quotas will reach individual businesses. It is to be able to read the proposal against the business’s own numbers when it arrives.

I would also distinguish documented demand from projections, and know what existing commercial commitments assume about federal production. These are planning considerations, not new obligations imposed by the latest notice.

The takeaway

The point is not that the DEA has announced production limits for medical cannabis businesses. It has not supplied the Schedule III amounts in this notice, and it has not said how, or whether, a national figure would translate to any individual registrant. DEA proposed 2027 APQ notice (PDF)

The point is that the quota piece of the April framework is now in motion, and that federal registration is one part of a larger federal picture, a theme I took up in the last Federal File. When the separate notice arrives, how the DEA built the number will deserve as much attention as the number itself.

Frequently asked questions

Does Schedule III status mean medical cannabis is exempt from production quotas?

No. The April framework expressly preserves applicable treaty-related quota requirements. Schedule III status should not be equated with unrestricted production. 91 Fed. Reg. 22,714 (Apr. 28, 2026) · 21 C.F.R. § 1301.13(k)

When will the Schedule III quotas be proposed?

The notice does not say. It states that the DEA is still evaluating data and methodologies and will publish the proposed Schedule III amounts in a separate notice. DEA proposed 2027 APQ notice (PDF)

Does this development authorize adult-use cannabis production?

No. DOJ has stated that the April framework covers qualifying medical marijuana activities, not recreational activities. The broader rescheduling proceeding remains separate. DOJ, Oct. 30, 2026

Attorney advertising. General information only, not legal advice. Reading this article does not create an attorney-client relationship.